MedTrace Logo

Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management

NCT07464808 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-03-11

No results posted yet for this study

Summary

This study aims to compare the efficacy of anti-Xa based versus weight-based enoxaparin dosing and to evaluate anti-Xa levels as a predictive tool for clinical outcomes in burn patients

Conditions

  • Venous Thromboembolic Event

Interventions

OTHER

follow up venous thrombo embolic events with routine clexan dose modification guided by anti factor 10 assay

follow up vte incidence and routine clexan dose modification

OTHER

follow up venous thromboembolic events with no routine clexan dosage modification and no usage of anti factor 10 assay

follow up of vte incidence with no routine dose modification unless indicated

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-28
Primary Completion
2027-01-30
Completion
2027-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07464808 on ClinicalTrials.gov